Deans' stroke musings: Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 3, 2024

Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria

How long before your competent? doctor puts together an EXACT DIET PROTOCOL that produces this beneficial gut microbiome? Or don't you have a functioning stroke doctor?

Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria

Published:April 02, 2024DOI:https://doi.org/10.1016/j.cell.2024.03.014

Highlights

•
Multiomic profiling in FHS reveals microbes and metabolites associated with CVD
•
Oscillibacter species are associated with decreased blood and stool cholesterol
•
Homology searches and molecular networking predict cholesterol enzymes and products
•
Oscillibacter species encode for conserved cholesterol-metabolizing enzymes

Summary

Accumulating evidence suggests that cardiovascular disease (CVD) is associated with an altered gut microbiome. Our understanding of the underlying mechanisms has been hindered by lack of matched multiomic data with diagnostic biomarkers. To comprehensively profile gut microbiome contributions to CVD, we generated stool metagenomics and metabolomics from 1,429 Framingham Heart Study participants. We identified blood lipids and cardiovascular health measurements associated with microbiome and metabolome composition. Integrated analysis revealed microbial pathways implicated in CVD, including flavonoid, γ-butyrobetaine, and cholesterol metabolism. Species from the Oscillibacter genus were associated with decreased fecal and plasma cholesterol levels. Using functional prediction and in vitro characterization of multiple representative human gut Oscillibacter isolates, we uncovered conserved cholesterol-metabolizing capabilities, including glycosylation and dehydrogenation. These findings suggest that cholesterol metabolism is a broad property of phylogenetically diverse Oscillibacter spp., with potential benefits for lipid homeostasis and cardiovascular health.